Everyday Health on MSN
C3G/IC-MPGN progression: Can new C3 inhibitors stop the path to dialysis?
For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...
The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
Cypher BioFollows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine releaseCommit is poised to nominate its first two clinical development candidates later in ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
• C3G and IgAN are kidney diseases where abnormal protein buildup in the kidneys’ filtering units leads to inflammation and damage, ultimately impairing kidney function. • Treatment for these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results